> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Reports Favorable Hypertension Drug Data
- URL: https://www.fdaweb.com/astrazeneca-reports-favorable-hypertension-drug-data/
- Published: 2025-10-07T12:00:00.000Z
- Updated: 2026-09-14T15:23:37.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159998

AstraZeneca says its investigational drug baxdrostat met the primary endpoint in the Phase 3 Bax24 trial, showing a statistically significant and clinically meaningful reduction in 24-hour ambulatory systolic blood pressure compared with placebo in patients with resistant hypertension. The 12-week study found that baxdrostat significantly lowered blood pressure throughout the full day-night cycle, including early morning hours — which the company says is typically when hypertensive patients face the greatest heart attack and stroke risks.

Baxdrostat is described as an oral, first-in-class inhibitor of aldosterone synthase, an enzyme that drives production of aldosterone — a hormone known to increase blood pressure and heighten cardiovascular risk. Phase 1 data showed that baxdrostat selectively suppresses aldosterone without affecting cortisol and maintains a half-life of about 26 to 30 hours, enabling once-daily dosing.

“This second Phase 3 trial demonstrates substantial and sustained improvement in blood pressure, reflecting baxdrostat’s long half-life and selective inhibition of aldosterone synthase,” the company says. “We’re advancing regulatory filings and developing baxdrostat as both a mono- and combination-therapy for conditions where aldosterone plays a key role, including chronic kidney disease and heart failure prevention.” It adds that the treatment was generally well tolerated, with a safety profile consistent with earlier studies, including the Phase 2 BaxHTN trial.